Copyright Reports & Markets. All rights reserved.

Global Choroidal Neovascularization Market Report 2018-2029

Request for Sample of this report
Buy now

1 Industry Overview of Choroidal Neovascularization

  • 1.1 Research Scope
  • 1.2 Market Segmentation by Types of Choroidal Neovascularization
  • 1.3 Market Segmentation by End Users of Choroidal Neovascularization
  • 1.4 Market Dynamics Analysis of Choroidal Neovascularization
    • 1.4.1 Market Drivers
    • 1.4.2 Market Challenges
    • 1.4.3 Market Opportunities
    • 1.4.4 Porter’s Five Forces

2 Major Manufacturers Analysis of Choroidal Neovascularization Industry

  • 2.1 Pfizer Inc.
    • 2.1.1 Company Overview
    • 2.1.2 Main Products and Specifications
    • 2.1.3 Choroidal Neovascularization Sales Volume, Revenue, Price and Gross Margin (2018-2023)
    • 2.1.4 Contact Information
  • 2.2 F. Hoffmann-La Roche Ltd.
    • 2.2.1 Company Overview
    • 2.2.2 Main Products and Specifications
    • 2.2.3 Choroidal Neovascularization Sales Volume, Revenue, Price and Gross Margin (2018-2023)
    • 2.2.4 Contact Information
  • 2.3 Novartis AG
    • 2.3.1 Company Overview
    • 2.3.2 Main Products and Specifications
    • 2.3.3 Choroidal Neovascularization Sales Volume, Revenue, Price and Gross Margin (2018-2023)
    • 2.3.4 Contact Information
  • 2.4 Regeneron Pharmaceuticals Inc.
    • 2.4.1 Company Overview
    • 2.4.2 Main Products and Specifications
    • 2.4.3 Choroidal Neovascularization Sales Volume, Revenue, Price and Gross Margin (2018-2023)
    • 2.4.4 Contact Information
  • 2.5 Bayer AG
    • 2.5.1 Company Overview
    • 2.5.2 Main Products and Specifications
    • 2.5.3 Choroidal Neovascularization Sales Volume, Revenue, Price and Gross Margin (2018-2023)
    • 2.5.4 Contact Information
  • 2.6 QLT Inc.
    • 2.6.1 Company Overview
    • 2.6.2 Main Products and Specifications
    • 2.6.3 Choroidal Neovascularization Sales Volume, Revenue, Price and Gross Margin (2018-2023)
    • 2.6.4 Contact Information
  • 2.7 Sanwa Kagaku Kenkyusho Co. Ltd.
    • 2.7.1 Company Overview
    • 2.7.2 Main Products and Specifications
    • 2.7.3 Choroidal Neovascularization Sales Volume, Revenue, Price and Gross Margin (2018-2023)
    • 2.7.4 Contact Information
  • 2.8 Promedior Inc.
    • 2.8.1 Company Overview
    • 2.8.2 Main Products and Specifications
    • 2.8.3 Choroidal Neovascularization Sales Volume, Revenue, Price and Gross Margin (2018-2023)
    • 2.8.4 Contact Information
  • 2.9 Valeant Pharmaceuticals International Inc.
    • 2.9.1 Company Overview
    • 2.9.2 Main Products and Specifications
    • 2.9.3 Choroidal Neovascularization Sales Volume, Revenue, Price and Gross Margin (2018-2023)
    • 2.9.4 Contact Information
  • 2.10 Gilead Sciences Inc
    • 2.10.1 Company Overview
    • 2.10.2 Main Products and Specifications
    • 2.10.3 Choroidal Neovascularization Sales Volume, Revenue, Price and Gross Margin (2018-2023)
    • 2.10.4 Contact Information

3 Global Choroidal Neovascularization Market Analysis by Regions, Manufacturers, Types and End Users

  • 3.1 Global Sales Volume and Revenue of Choroidal Neovascularization by Regions (2018-2023)
  • 3.2 Global Sales Volume and Revenue of Choroidal Neovascularization by Manufacturers (2018-2023)
  • 3.3 Global Sales Volume and Revenue of Choroidal Neovascularization by Types (2018-2023)
  • 3.4 Global Sales Volume and Revenue of Choroidal Neovascularization by End Users (2018-2023)
  • 3.5 Selling Price Analysis of Choroidal Neovascularization by Regions, Manufacturers, Types and End Users in (2018-2023)

4 Northern America Choroidal Neovascularization Market Analysis by Countries, Types and End Users

  • 4.1 Northern America Choroidal Neovascularization Sales Volume and Revenue Analysis by Countries (2018-2023)
  • 4.2 Northern America Choroidal Neovascularization Sales Volume and Revenue Analysis by Types (2018-2023)
  • 4.3 Northern America Choroidal Neovascularization Sales Volume and Revenue Analysis by End Users (2018-2023)
  • 4.4 United States Choroidal Neovascularization Sales Volume, Revenue, Import and Export Analysis (2018-2023)
  • 4.5 Canada Choroidal Neovascularization Sales Volume, Revenue, Import and Export Analysis (2018-2023)

5 Europe Choroidal Neovascularization Market Analysis by Countries, Types and End Users

  • 5.1 Europe Choroidal Neovascularization Sales Volume and Revenue Analysis by Countries (2018-2023)
  • 5.2 Europe Choroidal Neovascularization Sales Volume and Revenue Analysis by Types (2018-2023)
  • 5.3 Europe Choroidal Neovascularization Sales Volume and Revenue Analysis by End Users (2018-2023)
  • 5.4 Germany Choroidal Neovascularization Sales Volume, Revenue, Import and Export Analysis (2018-2023)
  • 5.5 France Choroidal Neovascularization Sales Volume, Revenue, Import and Export Analysis (2018-2023)
  • 5.6 UK Choroidal Neovascularization Sales Volume, Revenue, Import and Export Analysis (2018-2023)
  • 5.7 Italy Choroidal Neovascularization Sales Volume, Revenue, Import and Export Analysis (2018-2023)
  • 5.8 Russia Choroidal Neovascularization Sales Volume, Revenue, Import and Export Analysis (2018-2023)
  • 5.9 Spain Choroidal Neovascularization Sales Volume, Revenue, Import and Export Analysis (2018-2023)
  • 5.10 Netherlands Choroidal Neovascularization Sales Volume, Revenue, Import and Export Analysis (2018-2023)

6 Asia Pacific Choroidal Neovascularization Market Analysis by Countries, Types and End Users

  • 6.1 Asia Pacific Choroidal Neovascularization Sales Volume and Revenue Analysis by Countries (2018-2023)
  • 6.2 Asia Pacific Choroidal Neovascularization Sales Volume and Revenue Analysis by Types (2018-2023)
  • 6.3 Asia Pacific Choroidal Neovascularization Sales Volume and Revenue Analysis by End Users (2018-2023)
  • 6.4 China Choroidal Neovascularization Sales Volume, Revenue, Import and Export Analysis (2018-2023)
  • 6.5 Japan Choroidal Neovascularization Sales Volume, Revenue, Import and Export Analysis (2018-2023)
  • 6.6 Korea Choroidal Neovascularization Sales Volume, Revenue, Import and Export Analysis (2018-2023)
  • 6.7 India Choroidal Neovascularization Sales Volume, Revenue, Import and Export Analysis (2018-2023)
  • 6.8 Australia Choroidal Neovascularization Sales Volume, Revenue, Import and Export Analysis (2018-2023)
  • 6.9 Indonesia Choroidal Neovascularization Sales Volume, Revenue, Import and Export Analysis (2018-2023)
  • 6.10 Vietnam Choroidal Neovascularization Sales Volume, Revenue, Import and Export Analysis (2018-2023)

7 Latin America Choroidal Neovascularization Market Analysis by Countries, Types and End Users

  • 7.1 Latin America Choroidal Neovascularization Sales Volume and Revenue Analysis by Countries (2018-2023)
  • 7.2 Latin America Choroidal Neovascularization Sales Volume and Revenue Analysis by Types (2018-2023)
  • 7.3 Latin America Choroidal Neovascularization Sales Volume and Revenue Analysis by End Users (2018-2023)
  • 7.4 Brazil Choroidal Neovascularization Sales Volume, Revenue, Import and Export Analysis (2018-2023)
  • 7.5 Mexico Choroidal Neovascularization Sales Volume, Revenue, Import and Export Analysis (2018-2023)
  • 7.6 Argentina Choroidal Neovascularization Sales Volume, Revenue, Import and Export Analysis (2018-2023)
  • 7.7 Colombia Choroidal Neovascularization Sales Volume, Revenue, Import and Export Analysis (2018-2023)

8 Middle East & Africa Choroidal Neovascularization Market Analysis by Countries, Types and End Users

  • 8.1 Middle East & Africa Choroidal Neovascularization Sales Volume and Revenue Analysis by Countries (2018-2023)
  • 8.2 Middle East & Africa Choroidal Neovascularization Sales Volume and Revenue Analysis by Types (2018-2023)
  • 8.3 Middle East & Africa Choroidal Neovascularization Sales Volume and Revenue Analysis by End Users (2018-2023)
  • 8.4 Turkey Choroidal Neovascularization Sales Volume, Revenue, Import and Export Analysis (2018-2023)
  • 8.5 Saudi Arabia Choroidal Neovascularization Sales Volume, Revenue, Import and Export Analysis (2018-2023)
  • 8.6 South Africa Choroidal Neovascularization Sales Volume, Revenue, Import and Export Analysis (2018-2023)
  • 8.7 Egypt Choroidal Neovascularization Sales Volume, Revenue, Import and Export Analysis (2018-2023)

9 Marketing Channel, Distributors and Traders Analysis

  • 9.1 Marketing Channel
    • 9.1.1 Direct Channel
    • 9.1.2 Indirect Channel
  • 9.2 Distributors and Traders

10 Global Choroidal Neovascularization Market Forecast by Regions, Countries, Manufacturers, Types and End Users

  • 10.1 Global Sales Volume and Revenue Forecast of Choroidal Neovascularization by Regions (2024-2029)
  • 10.2 Global Sales Volume and Revenue Forecast of Choroidal Neovascularization by Types (2024-2029)
  • 10.3 Global Sales Volume and Revenue Forecast of Choroidal Neovascularization by End Users (2024-2029)
  • 10.4 Global Revenue Forecast of Choroidal Neovascularization by Countries (2024-2029)
    • 10.4.1 United States Revenue Forecast (2024-2029)
    • 10.4.2 Canada Revenue Forecast (2024-2029)
    • 10.4.3 Germany Revenue Forecast (2024-2029)
    • 10.4.4 France Revenue Forecast (2024-2029)
    • 10.4.5 UK Revenue Forecast (2024-2029)
    • 10.4.6 Italy Revenue Forecast (2024-2029)
    • 10.4.7 Russia Revenue Forecast (2024-2029)
    • 10.4.8 Spain Revenue Forecast (2024-2029)
    • 10.4.9 Netherlands Revenue Forecast (2024-2029)
    • 10.4.10 China Revenue Forecast (2024-2029)
    • 10.4.11 Japan Revenue Forecast (2024-2029)
    • 10.4.12 Korea Revenue Forecast (2024-2029)
    • 10.4.13 India Revenue Forecast (2024-2029)
    • 10.4.14 Australia Revenue Forecast (2024-2029)
    • 10.4.15 Indonesia Revenue Forecast (2024-2029)
    • 10.4.16 Vietnam Revenue Forecast (2024-2029)
    • 10.4.17 Brazil Revenue Forecast (2024-2029)
    • 10.4.18 Mexico Revenue Forecast (2024-2029)
    • 10.4.19 Argentina Revenue Forecast (2024-2029)
    • 10.4.20 Colombia Revenue Forecast (2024-2029)
    • 10.4.21 Turkey Revenue Forecast (2024-2029)
    • 10.4.22 Saudi Arabia Revenue Forecast (2024-2029)
    • 10.4.23 South Africa Revenue Forecast (2024-2029)
    • 10.4.24 Egypt Revenue Forecast (2024-2029)

11 Industry Chain Analysis of Choroidal Neovascularization

  • 11.1 Upstream Major Raw Materials and Equipment Suppliers Analysis of Choroidal Neovascularization
    • 11.1.1 Major Raw Materials Suppliers with Contact Information Analysis of Choroidal Neovascularization
    • 11.1.2 Major Equipment Suppliers with Contact Information Analysis of Choroidal Neovascularization
  • 11.2 Downstream Major Consumers Analysis of Choroidal Neovascularization
  • 11.3 Major Suppliers of Choroidal Neovascularization with Contact Information
  • 11.4 Supply Chain Relationship Analysis of Choroidal Neovascularization

12 Choroidal Neovascularization New Project Investment Feasibility Analysis

  • 12.1 Choroidal Neovascularization New Project SWOT Analysis
  • 12.2 Choroidal Neovascularization New Project Investment Feasibility Analysis
    • 12.2.1 Project Name
    • 12.2.2 Investment Budget
    • 12.2.3 Project Product Solutions
    • 12.2.4 Project Schedule

13 Choroidal Neovascularization Research Findings and Conclusion

    14 Appendix

    • 14.1 Research Methodology
    • 14.2 References and Data Sources
      • 14.2.1 Primary Sources
      • 14.2.2 Secondary Paid Sources
      • 14.2.3 Secondary Public Sources
    • 14.3 Abbreviations and Units of Measurement
    • 14.4 Author Details

    The Choroidal Neovascularization industry is witnessing significant growth as it provides innovative treatments for vision-threatening conditions. Choroidal Neovascularization (CNV) refers to the abnormal growth of blood vessels beneath the retina, leading to severe vision impairment. This industry offers medical interventions that target CNV, with a primary focus on conditions such as Extreme Myopia, Malignant Myopic Degeneration, and Age-Related Developments. With a projected global market size of US$5,380 million in 2022 and a compound annual growth rate of 6.8%, the Choroidal Neovascularization industry holds promising prospects for the future of ocular interventions.

    Definition and Use:
    Choroidal Neovascularization is a condition characterized by the formation of abnormal blood vessels within the choroid layer of the eye, which can lead to leakage and bleeding, resulting in vision loss or distortion. The growth of these new blood vessels is typically driven by factors such as inflammation, age-related changes, and myopia progression.

    The Choroidal Neovascularization industry focuses on developing medical interventions to address the underlying causes and symptoms associated with CNV. These interventions aim to inhibit the growth of abnormal blood vessels, reduce leakage, and preserve or restore visual function. They may include pharmacological agents, gene therapies, laser treatments, or a combination of approaches tailored to individual patient needs.

    Industry Status:
    The global Choroidal Neovascularization market is expected to reach a value of US$5,380 million in 2022. The industry's growth is fueled by various factors, including an increasing prevalence of CNV-related conditions, advancements in treatment technologies, and rising awareness among healthcare professionals and patients.

    The market expansion in the Choroidal Neovascularization industry is driven by the advantages it offers in managing vision-threatening conditions. By effectively targeting CNV, these interventions can stabilize or improve patients' visual acuity and quality of life. Furthermore, advancements in diagnostic techniques, such as optical coherence tomography (OCT) imaging, have facilitated early detection and prompt intervention, driving the demand for CNV treatments.

    Major Manufacturers:
    The Choroidal Neovascularization industry is dominated by several global manufacturers committed to innovation, research, and development. Key players in this market include Pfizer Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Regeneron Pharmaceuticals Inc., Bayer AG, QLT Inc., Sanwa Kagaku Kenkyusho Co. Ltd., Promedior Inc., Valeant Pharmaceuticals International Inc., and Gilead Sciences Inc. These companies invest significantly in clinical trials, regulatory compliance, and collaborations to advance treatment options and improve patient outcomes.

    Prospects and Opportunities:
    The Choroidal Neovascularization industry presents substantial prospects for growth and advancement in the coming years.

    Technological Advancements: Continued research and technological innovations hold potential for developing more effective and targeted interventions for CNV. This includes advancements in drug delivery systems, gene therapies, and imaging technologies, enabling more precise diagnosis and treatment planning.
    Evolving Therapeutic Approaches: Emerging treatments like anti-vascular endothelial growth factor (anti-VEGF) drugs and combination therapies show promising results in halting CNV progression and improving visual function. Further exploration of these approaches can revolutionize the industry.
    Market Expansion: The increasing prevalence of CNV-related conditions, coupled with an aging population, highlights significant market expansion opportunities globally. Expanding awareness among healthcare providers and patients about the availability and benefits of CNV interventions will further drive market growth.
    Collaborative Research Efforts: Collaboration between manufacturers, academic institutions, and research organizations fosters the development of innovative treatment modalities, encourages knowledge sharing, and enhances the overall understanding of CNV pathophysiology and management.
    Patient-Centric Approach: Improved patient education and awareness programs can empower individuals with CNV-related conditions to seek timely interventions and adhere to treatment plans, leading to better outcomes.
    Conclusion:
    The Choroidal Neovascularization industry is experiencing robust growth as it addresses vision-threatening conditions associated with abnormal blood vessel growth in the choroid layer of the eye. With a projected market size of US$5,380 million in 2022 and a compound annual growth rate of 6.8%, the industry presents significant prospects for the future.

    Choroidal Neovascularization interventions offer innovative approaches to manage conditions such as Extreme Myopia, Malignant Myopic Degeneration, and Age-Related Developments. Major manufacturers like Pfizer Inc., F. Hoffmann-La Roche Ltd., and Novartis AG play a critical role in advancing treatment options and enhancing patient outcomes through research, development, and collaboration.

    The industry's growth is supported by technological advancements, evolving therapeutic approaches, expanding market opportunities, collaborative research efforts, and patient-centric initiatives. Continued investment in these areas will contribute to the industry's success and improve the quality of life for individuals affected by CNV-related conditions worldwide.

    The SWOT analysis of the Choroidal Neovascularization industry is as follows:

    Strengths:
    Innovative Treatment Options: The CNV industry provides innovative treatments for vision-threatening conditions, offering patients new possibilities for preserving or restoring their visual function.
    Technological Advancements: Advancements in diagnostic techniques and treatment technologies, such as optical coherence tomography (OCT) imaging and anti-vascular endothelial growth factor (anti-VEGF) drugs, have improved the accuracy and efficacy of CNV interventions.
    Growing Market Size: The CNV industry has experienced significant market growth, with a projected market size of US$5,380 million in 2022. This indicates a strong demand for CNV treatments.
    Collaboration Opportunities: Collaboration between manufacturers, academic institutions, and research organizations fosters innovation, knowledge sharing, and the development of new treatment modalities.

    Weaknesses:
    Cost of Treatments: Some CNV interventions can be expensive, making them less accessible to patients who may not have adequate financial resources or insurance coverage.
    Potential Side Effects: Certain treatments, such as anti-VEGF injections, may carry risks of side effects or complications, which can affect patient adherence and satisfaction.
    Limited Awareness: The CNV industry may face challenges in raising awareness among healthcare providers and patients about the availability, benefits, and importance of early intervention for CNV-related conditions.

    Opportunities:
    Market Expansion: The increasing prevalence of CNV-related conditions, coupled with an aging population, presents opportunities for market expansion globally.
    Technological Advancements: Continued research and development efforts can lead to the discovery of more effective and targeted interventions, improving patient outcomes and expanding the range of treatment options.
    Rising Demand for Vision Care: The growing emphasis on maintaining visual health and the increasing demand for ocular interventions create favorable market conditions for the CNV industry.
    Patient-Centric Approach: Implementing patient education and awareness programs can empower individuals with CNV-related conditions to seek timely interventions and improve treatment adherence.

    Threats:
    Regulatory Challenges: The CNV industry must navigate regulatory requirements and obtain necessary approvals for new treatments, which can be time-consuming and costly.
    Competition: The industry faces competition from other ocular intervention fields and alternative treatment modalities, which may limit market share and growth opportunities.
    Economic Factors: Economic fluctuations, changes in healthcare policies, and reimbursement issues can impact the affordability and accessibility of CNV interventions.
    COVID-19 Pandemic: The ongoing pandemic has caused disruptions in healthcare systems and patient access to treatments, potentially affecting the demand for CNV interventions.

    Key players in global Choroidal Neovascularization market include:
    Pfizer Inc.
    F. Hoffmann-La Roche Ltd.
    Novartis AG
    Regeneron Pharmaceuticals Inc.
    Bayer AG
    QLT Inc.
    Sanwa Kagaku Kenkyusho Co. Ltd.
    Promedior Inc.
    Valeant Pharmaceuticals International Inc.
    Gilead Sciences Inc

    Market segmentation, by product types:
    Intravenous
    Intravitreal

    Market segmentation, by applications:
    Extreme Myopia
    Malignant Myopic Degeneration
    Age-Related Developments
    Buy now